DSSG Group: Basket (multiple types)

Patients who are due to receive neoadjuvant chemotherapy or chemoradiation for early-stage locally advanced breast cancer or gastrointestinal cancers.

The main purpose of the study is to determine whether there is a change in the gut microbiome (GM) before and after neo-adjuvant chemotherapy or chemoradiation for early-stage locally advanced Breast or Gastrointestinal (GI) cancers and to examine the association of this change in the GM with pathological response at the time of surgery.

With a solid tumour and whose tumour has been profiled with a next-generation sequencing (NGS) test.

WAYFIND-R aims to enable collaborations and to provide meaningful insights and high-quality evidence to enhance our understanding of precision oncology and ultimately transform the lives of people with cancer.

Oligometastatic disease who have one controlled primary solid tumour and 1-3 current metastatic lesions, and a maximum of 8 lifetime metastatic lesions

The purpose of the study is to assess the impact of Stereotactic Ablative Radiotherapy (SABR), compared to standard of care (SOC) treatment, on overall survival, oncologic outcomes, and quality of life in patients with 1-3 current metastatic lesions.

Multiple types of cancer

This study will evaluate the efficacy and safety of olaparib monotherapy in participants with multiple types of advanced cancer (unresectable and/or metastatic).